Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00005955 · ClinicalTrials.gov registry record · Phase 2

Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors

A Phase 2 study, sponsored by Duke University.

Completed
Registry status
Phase 2
Development phase

NCT00005955: Completed Phase 2 study, sponsored by Duke University.

NCT00005955 is a Phase 2 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00005955, a Phase 2 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemotherapy combined with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of temozolomide followed by radiation therapy in treating children who have newly diagnosed malignant central nervous system tumors.

Interventions

  • DRUG temozolomide

Trial Details

FieldValue
Start Date 2000-08
Est. Completion 2002-09
Phase Phase 2
Duke University

1,725 total trials

What the finished NCT00005955 record still lists

NCT00005955 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which temozolomide is the first listed.

NCT00005955 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00005955 about?

NCT00005955 is a clinical study titled "Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemotherapy combined with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effec...

What is the current status of trial NCT00005955?

This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2002-09.

What interventions are being tested in trial NCT00005955?

The interventions under investigation include: temozolomide (DRUG).

Who is sponsoring clinical trial NCT00005955?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00005955, the US trial registry maintained by the National Library of Medicine. NCT00005955 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.